Tranexamic acid: from dermatological discovery to anti-ageing cosmetic innovation

A multi-faceted mode of action for the skin

Tranexamic acid attracts so much interest because it acts at several biological levels to improve the health and appearance of the skin. Its main mechanisms of action – established by recent research – can be summarised as follows:

• Regulation of melanin production: TXA directly targets melanogenesis (the formation of pigment). On the one hand, it has a structural analogy with tyrosinase – the key enzyme in melanin synthesis – and could therefore compete with it, disrupting the pigmentation process. On the other hand, by blocking the UV-induced activation of plasminogen in keratinocytes, it interferes with the dialogue between skin cells (keratinocytes and melanocytes) and reduces the release of pro-melanogenic mediators such as arachidonic acid and prostaglandins. TXA has been shown in particular to inhibit the effect of PGE2 (prostaglandin E2), an inflammatory molecule capable of stimulating melanocytes. The net effect is a decrease in melanin synthesis through several pathways, which translates clinically into fading of brown marks and a more even skin tone.

• Anti-inflammatory action: tranexamic acid also has an anti-inflammatory role in the skin. By inhibiting plasmin, it reduces the activation of certain immune cells and the production of pro-inflammatory cytokines (such as IL-6 and TNF-α) observed when the skin is under attack. Studies have shown that it limits the infiltration of inflammatory cells into the skin and at the same time raises levels of IL-10, a protective anti-inflammatory cytokine. This property is particularly useful for skin prone to redness or chronic irritation, especially as inflammation plays an aggravating role in some hyperpigmentation (post-acne marks, for example). By calming inflammation, TXA helps not only to lighten post-inflammatory brown marks, but potentially also to slow inflammation-driven skin ageing (inflam’aging).

• Effect on vascularisation and redness: less well known is that TXA has anti-angiogenic properties, meaning that it can reduce the formation of new blood vessels in the skin. As plasmin promotes angiogenesis, its inhibition by TXA leads to a decrease in factors such as VEGF (vascular endothelial growth factor) and endothelin-1, which are involved in the dilation and growth of capillaries. Experiments on rosacea models have shown that tranexamic acid reduces redness and the density of abnormal microvessels. For cosmetics, this opens the way to using the ingredient not only against brown marks, but also to improve dull complexions with diffuse redness or post-lesional erythema. By targeting both pigment and the vascular component, TXA helps to even out the overall skin tone.

• Repair of the skin barrier: in another promising area, tranexamic acid appears to speed up the restoration of a damaged skin barrier. Researchers have observed that topical application of TXA stimulates the production of epidermal lipids by modulating the activity of certain proteases and cell receptors (PAR-2) involved in barrier homeostasis. In practical terms, on skin whose barrier has been impaired (by irritating treatments, allergies or external aggressors), a cream containing 5% tranexamic acid was able to speed up regeneration of the epidermis and raise levels of tight junction proteins such as occludin, a sign of better cell cohesion. By strengthening the barrier, TXA contributes to more resilient skin that is less prone to dehydration and irritants, which is an indirect anti-ageing benefit (an intact barrier prevents premature ageing linked to skin stress).

Thanks to this synergistic range of actions – anti-melanin, anti-inflammatory, anti-redness and pro-barrier – tranexamic acid acts as a true conductor of skin homeostasis. This multifunctional approach earns it a prime place among modern dermatological actives, because it addresses several mechanisms of ageing and pigmentary disorders at once.

Clinical efficacy and benefits for pigmentation marks

Specialists’ enthusiasm for tranexamic acid is backed by a growing number of scientific studies demonstrating its efficacy on pigmentation problems. In melasma in particular (the “mask of pregnancy”), TXA has become one of the most reliable treatments of the last decade. Meta-analyses confirm that tranexamic acid, even at a low dose (around 500 mg/day orally), brings significant improvement in melasma within 8 to 12 weeks in most patients. A study published in Dermatology and Therapy reported that 96% of participants showed clear fading of their marks after 12 weeks of daily treatment with a tranexamic acid product, combined with broad-spectrum sun protection. Interestingly, the efficacy obtained was judged comparable to that of 4% hydroquinone cream – the historic anti-dark spot standard – without its irritating side effects. Moreover, the benefit of TXA is not limited to melasma: clinical trials have shown convincing results in post-inflammatory hyperpigmentation (acne marks, for example) and post-laser pigmented lesions, with improved skin tone and reduced marks observed within a few months of treatment.

The route of administration can, however, influence results. Taken orally, tranexamic acid spreads through the circulation and appears particularly effective on resistant melasma (under strict medical supervision because of rare thrombotic risks). In topical use, results are also encouraging, though more variable – partly because TXA, as a hydrophilic molecule, has difficulty penetrating the skin. Concentrations of 2% to 5% in creams are generally recommended to obtain a noticeable lightening effect. Several comparative studies indicate that, applied locally, TXA at 3-5% can lighten melasma in a similar way to hydroquinone within a few months, while causing less irritation and fewer pigmentary rebound effects. These data have led major dermocosmetic brands to formulate tranexamic acid serums, often combining it with other complementary actives (niacinamide, vitamin C, kojic acid, etc.) to tackle marks on all fronts. For example, adding niacinamide (vitamin B3) can act on both inflammation and the regulation of melanin transfer, while vitamin C contributes its antioxidant and lightening effect. A recent study of 55 women with moderate hyperpigmentation showed that a serum combining 3% tranexamic acid + 5% niacinamide + 1% kojic acid led to a significant reduction in marks and a visibly more even skin tone in 12 weeks compared with a placebo.

Beyond efficacy, one of the main strengths of tranexamic acid is its tolerance profile. Applied topically, it is suitable even for sensitive skin, because it generally causes neither irritation nor noticeable peeling – unlike other, more aggressive depigmenting actives. Studies and clinical feedback report very few adverse effects from local application: at worst, some transient redness or tingling linked to the formula, but no severe reactions. A 5-year follow-up of patients taking oral TXA (650 mg/day) found no thrombotic events or serious side effects, pointing to good safety in use under supervision. In addition, since tranexamic acid is not photosensitising, it can be used all year round (including in summer), which is an advantage for treating conditions such as melasma that often require continuous maintenance. Daily sun protection nevertheless remains essential alongside it, to optimise results and prevent marks from reappearing during treatment.

Finally, tranexamic acid suits a wide range of users: “All skin types, all ages and all skin tones with hyperpigmentation can use it daily”, notes an article by dermatologist Debra Jaliman. This universality makes it a preferred choice in professional skincare aimed at evening out skin tone without compromising on tolerance.

From dermatology to cosmetics: a new anti-ageing essential

The journey of tranexamic acid, from the operating theatre to the shelves of cosmetic laboratories, shows how a scientific innovation can redefine skincare routines. Long confined to the treatment of resistant pigmentary disorders, TXA is now promoted as a versatile, highly fashionable anti-ageing ingredient in premium cosmetics. This rise is explained by the convergence of its many benefits for younger-looking skin: by fading brown marks and acne marks, it brings radiance and freshness to the complexion; by calming chronic inflammation, it helps prevent premature ageing caused by skin stress; by strengthening the skin barrier, it improves the overall quality of the skin, which becomes softer and less reactive. In other words, tranexamic acid offers a dual anti-dark spot and anti-ageing action that formulators and dermatologists alike are seeking.

This trend is part of a broader movement in cosmetics towards smart, multifunctional formulas. Rather than multiplying products, B2B professionals in the industry are incorporating actives such as tranexamic acid that can target several mechanisms of skin ageing at once. For example, “all-in-one” creams are emerging in which TXA is combined with smoothing peptides or natural retinoid-like ingredients (bakuchiol) to address wrinkles, dark spots and loss of elasticity at the same time. This synergistic approach makes it possible to offer complete, effective skincare that respects the skin’s balance and avoids an accumulation of potentially irritating products.

Recent technological developments have also helped to maximise the impact of tranexamic acid in cosmetics. Aware of how poorly this hydrophilic ingredient is absorbed through the skin, researchers have developed innovative encapsulation systems (polymer nanospheres, liposomes) to improve its penetration. A 2024 study showed that encapsulating TXA in lipid nanocapsules markedly increased its lightening power in vitro: at equal doses, the liposomal form reduced the melanin content of a reconstructed skin model more than the free form did, with the same efficacy using half as much active ingredient. These advances open the way to more effective topical products, capable of delivering tranexamic acid deep into the epidermis, where it can exert its full effect. For cosmetic brands, investing in such formulation technologies is a way to stand out by offering products that are both scientifically advanced and focused on results for pigmentation problems and ageing.

In terms of storytelling, tranexamic acid also gives cosmetics professionals a good narrative. It embodies the bridge between medicine and beauty, with its fascinating story of a chance discovery that became a global innovation. Communicating to consumers about an ingredient “inherited from dermatology”, proven by clinical studies and adopted by experts, reinforces the credibility of the products that contain it. In addition, its recent popularity – it is often described as the “new star of tone-evening skincare” – feeds the marketing trend of “skinimalism” (doing less, but better): a single active to target dark spots, redness and signs of ageing is the promise of a simplified, effective routine.